GHK-Cu is one of the most extensively studied copper-binding peptides in regenerative and dermatological research. This article provides an educational overview of what the published scientific literature reports about GHK-Cu, its structure, and its mechanisms of interest. All information below is provided strictly for research and informational purposes.
What is GHK-Cu?
GHK-Cu is a copper complex of the tripeptide GHK (glycyl-L-histidyl-L-lysine) — a short chain of three amino acids bound to a copper ion. It was first isolated from human plasma in 1973. Because the GHK peptide has a high affinity for copper ions, it commonly exists and is studied as the copper complex, GHK-Cu. In cosmetic ingredient listings it is sometimes referred to as Copper Tripeptide-1. It is typically supplied as a lyophilised powder for research use.
Mechanisms of interest
Scientific interest in GHK-Cu centres on its reported activity in tissue and extracellular-matrix research. The published literature describes its study in relation to:
- Collagen and extracellular-matrix synthesis — research has examined its association with collagen and elastin production and fibroblast activity in skin-tissue models.
- Wound-healing pathways — multiple animal studies have investigated its role in wound-closure and tissue-regeneration models.
- Gene-expression effects — published work has explored its reported influence on the expression of a broad range of genes, including matrix metalloproteinases (MMP-1, MMP-2) and their regulators.
- Angiogenesis — studies have looked at its association with new blood-vessel formation in healing models.
What the research has reported
GHK-Cu has been studied across in-vitro work, animal models, and some human cosmetic clinical trials. The strongest body of published evidence relates to skin and wound-healing research. Animal studies have reported effects on collagen accumulation and wound closure, and small human trials in topical cosmetic contexts have examined skin-related measures. Researchers note that while the mechanisms are well characterised in laboratory settings, broader clinical validation is still developing, and some literature highlights that observed effects may relate to the copper ion itself as well as the peptide.
Regulatory status in Australia
GHK-Cu is widely used as an ingredient in topical cosmetic products. As supplied for laboratory research, it is not approved by the Therapeutic Goods Administration (TGA) as a therapeutic good and is not listed on the Australian Register of Therapeutic Goods (ARTG) for therapeutic use. It is supplied strictly as a research compound.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. GHK-Cu is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.